Cargando…
A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models
Oncolytic viruses have shown excellent safety profiles in preclinical and clinical studies; however, in most cases therapeutic benefits have been modest. We have previously reported the generation of a chimeric poxvirus (CF33), with significantly improved oncolytic characteristics, through chimeriza...
Autores principales: | Chaurasiya, Shyambabu, Chen, Nanhai G., Lu, Jianming, Martin, Nikolas, Shen, Yinan, Kim, Sang-In, Warner, Susanne G., Woo, Yanghee, Fong, Yuman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170804/ https://www.ncbi.nlm.nih.gov/pubmed/31209267 http://dx.doi.org/10.1038/s41417-019-0114-x |
Ejemplares similares
-
A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression
por: Warner, Susanne G., et al.
Publicado: (2019) -
An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model
por: Chaurasiya, Shyambabu, et al.
Publicado: (2023) -
A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection
por: O’Leary, Michael P., et al.
Publicado: (2018) -
Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose
por: O’Leary, Michael P., et al.
Publicado: (2018) -
A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer
por: Chaurasiya, Shyambabu, et al.
Publicado: (2021)